IL152747A0 - Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells - Google Patents
Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cellsInfo
- Publication number
- IL152747A0 IL152747A0 IL15274701A IL15274701A IL152747A0 IL 152747 A0 IL152747 A0 IL 152747A0 IL 15274701 A IL15274701 A IL 15274701A IL 15274701 A IL15274701 A IL 15274701A IL 152747 A0 IL152747 A0 IL 152747A0
- Authority
- IL
- Israel
- Prior art keywords
- presentation
- dendritic cells
- therapeutic method
- composition utilizing
- utilizing antigen
- Prior art date
Links
- 238000010668 complexation reaction Methods 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20363500P | 2000-05-11 | 2000-05-11 | |
US25367100P | 2000-11-28 | 2000-11-28 | |
US25395600P | 2000-11-28 | 2000-11-28 | |
PCT/IB2001/001238 WO2001085203A2 (fr) | 2000-05-11 | 2001-05-11 | Methode et composition therapeutiques utilisant la complexation antigene-anticorps et la presentation par des cellules dendritiques |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152747A0 true IL152747A0 (en) | 2003-06-24 |
Family
ID=27394574
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15274801A IL152748A0 (en) | 2000-05-11 | 2001-05-11 | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
IL15274701A IL152747A0 (en) | 2000-05-11 | 2001-05-11 | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15274801A IL152748A0 (en) | 2000-05-11 | 2001-05-11 | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
Country Status (7)
Country | Link |
---|---|
US (3) | US20020048583A1 (fr) |
EP (2) | EP1294397A2 (fr) |
JP (2) | JP2003532687A (fr) |
AU (4) | AU2001267780B2 (fr) |
CA (2) | CA2408549A1 (fr) |
IL (2) | IL152748A0 (fr) |
WO (2) | WO2001085203A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
CA2333221A1 (fr) * | 1998-06-15 | 1999-12-23 | Altarex Corp. | Compositions therapeutiques produisant une reponse immunitaire par renouvellement des antigenes |
WO2003086041A2 (fr) * | 2002-04-11 | 2003-10-23 | Altarex Medical Corporation | Agents de liaison et leur utilisation dans le ciblage de cellules tumorales |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
PT2891666T (pt) | 2002-10-16 | 2017-09-22 | Purdue Pharma Lp | Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização |
AU2003286463A1 (en) * | 2002-10-17 | 2004-05-04 | Altarex Medical Corp. | Therapeutic adjuvant |
US7279451B2 (en) | 2002-10-25 | 2007-10-09 | Honeywell International Inc. | Compositions containing fluorine substituted olefins |
US8246959B1 (en) | 2003-08-01 | 2012-08-21 | University Of Washington | Dendritic cell-associated lectin-like molecules, compositions and methods of use |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
TWI482748B (zh) | 2005-06-24 | 2015-05-01 | Honeywell Int Inc | 含有經氟取代之烯烴之組合物 |
ZA200804078B (en) * | 2005-10-13 | 2009-09-30 | Virexx Medical Corp | Chimeric hepatitis C virus antigens for eliciting an immune response |
US20080095790A1 (en) * | 2006-10-24 | 2008-04-24 | Perambakam Supriya M | Methods of Treating Prostate Cancer |
NZ578657A (en) * | 2007-02-02 | 2012-02-24 | Baylor Res Inst | Multivariable antigens complexed with targeting humanized monoclonal antibody |
EP2331130B1 (fr) * | 2008-04-09 | 2018-02-14 | Oncoquest Inc. | Anticorps d'ige pour le traitement du cancer |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
WO2010120897A1 (fr) * | 2009-04-14 | 2010-10-21 | Northeastern Ohio Universities College Of Medicine | Compositions et méthodes destinées à la modulation des réponses immunogènes par activation des cellules dendritiques |
IN2012DN01663A (fr) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
CA2782194C (fr) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combinaison d'anticorps radio-marquees et de conjugues anticorps-medicament pour le traitement du cancer pancreatique |
WO2012006634A2 (fr) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Thérapie peptidique par antigène prostatique spécifique (psa) |
US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
EP2492689B8 (fr) * | 2011-02-22 | 2013-12-25 | Bernhard-Nocht-Institut für Tropenmedizin | Détection des anticorps à l'aide d'un complexe immun amélioré ELISA |
CA2831572C (fr) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume |
EP2885002A4 (fr) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies |
LT2900277T (lt) | 2012-12-13 | 2022-04-11 | Immunomedics, Inc. | Antikūnų ir sn-38 imunokonjugatų dozės, skirtos pagerintam veiksmingumui ir sumažintam toksiškumui |
EP3107577B1 (fr) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Traitement d'une maladie par induction d'une réponse immune à des cellules exprimant le trop-2 |
WO2015130416A1 (fr) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Anticorps rfb4 humanisés anti-cd22 |
WO2015200260A1 (fr) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Thérapie par anti-histone pour nécrose vasculaire dans la glomérulonéphrite sévère |
CA2961774C (fr) | 2014-10-07 | 2023-05-23 | Immunomedics, Inc. | Utilisation neoadjuvante de conjugues anticorps-medicaments |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
CA2983597A1 (fr) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoi nositide 3-kinase ameliorant considerablement un resultat therapeutique de cancer |
EP3316885B1 (fr) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Immunoconjugués d'anticorps sn-38 avec un lieur cl2a |
JPWO2022239720A1 (fr) | 2021-05-10 | 2022-11-17 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3583420B2 (ja) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
DE19534630A1 (de) | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
US6251665B1 (en) * | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
US5896745A (en) * | 1997-04-29 | 1999-04-27 | General Dynamics Defense Systems, Inc. | Swashplate assemblies for infinitely variable hydrostatic transmissions |
EP2058389B1 (fr) * | 1997-10-27 | 2016-05-18 | Rockefeller University | Milieu défini pour la maturation des cellules dendritiques comprenand TNF-alpha, IL-1beta, IL-6 |
CA2333221A1 (fr) * | 1998-06-15 | 1999-12-23 | Altarex Corp. | Compositions therapeutiques produisant une reponse immunitaire par renouvellement des antigenes |
DE69942742D1 (de) * | 1998-06-15 | 2010-10-21 | Quest Pharmatech Inc | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
-
2001
- 2001-05-11 JP JP2001581857A patent/JP2003532687A/ja active Pending
- 2001-05-11 US US09/853,300 patent/US20020048583A1/en not_active Abandoned
- 2001-05-11 EP EP01945568A patent/EP1294397A2/fr not_active Withdrawn
- 2001-05-11 WO PCT/IB2001/001238 patent/WO2001085203A2/fr active Application Filing
- 2001-05-11 AU AU2001267780A patent/AU2001267780B2/en not_active Ceased
- 2001-05-11 CA CA002408549A patent/CA2408549A1/fr not_active Abandoned
- 2001-05-11 IL IL15274801A patent/IL152748A0/xx unknown
- 2001-05-11 EP EP01949830A patent/EP1294398A2/fr not_active Withdrawn
- 2001-05-11 IL IL15274701A patent/IL152747A0/xx unknown
- 2001-05-11 US US09/853,268 patent/US6689355B2/en not_active Expired - Lifetime
- 2001-05-11 AU AU2001270942A patent/AU2001270942A1/en not_active Abandoned
- 2001-05-11 JP JP2001581856A patent/JP2003532686A/ja active Pending
- 2001-05-11 CA CA002408547A patent/CA2408547A1/fr not_active Abandoned
- 2001-05-11 WO PCT/IB2001/001331 patent/WO2001085204A2/fr not_active Application Discontinuation
- 2001-05-11 AU AU6778001A patent/AU6778001A/xx active Pending
-
2003
- 2003-10-10 US US10/683,510 patent/US20040191236A1/en not_active Abandoned
-
2006
- 2006-10-13 AU AU2006228067A patent/AU2006228067A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001085203A3 (fr) | 2002-08-22 |
US20020048583A1 (en) | 2002-04-25 |
CA2408549A1 (fr) | 2001-11-15 |
WO2001085204A2 (fr) | 2001-11-15 |
JP2003532687A (ja) | 2003-11-05 |
WO2001085203A2 (fr) | 2001-11-15 |
US6689355B2 (en) | 2004-02-10 |
AU2006228067A1 (en) | 2006-11-02 |
CA2408547A1 (fr) | 2001-11-15 |
AU6778001A (en) | 2001-11-20 |
JP2003532686A (ja) | 2003-11-05 |
US20040191236A1 (en) | 2004-09-30 |
IL152748A0 (en) | 2003-06-24 |
US20020164312A1 (en) | 2002-11-07 |
AU2001270942A1 (en) | 2001-11-20 |
EP1294398A2 (fr) | 2003-03-26 |
WO2001085204A3 (fr) | 2002-08-22 |
EP1294397A2 (fr) | 2003-03-26 |
AU2001267780B2 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL152747A0 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
HUS2000035I1 (hu) | Antitest-kompozíciót termelõ sejt | |
IL160720A0 (en) | Composition and methods for priming monocytic dendritic cells and t cells for th-1 response | |
AU2002213007A1 (en) | Golf simulator | |
AU2001236916A1 (en) | Techniques to facilitate shopping for projects | |
GB0200425D0 (en) | Methods and compositions fo assaying analytes | |
GB0106184D0 (en) | Special call-free charging method | |
AU1368502A (en) | An automated music arranger | |
EP1165773A4 (fr) | Plate-forme perfectionnee de presentation d'antigenes | |
GB2367752B (en) | Completely reproducible articulator | |
EP1277459A4 (fr) | Compositions de frisage et methode de frisage utilisant ces compositions | |
EP1237929A4 (fr) | Anticorps presentant une specificite pour des cellules dendritiques | |
AU2001261697A1 (en) | Methods for identifying novel therapeutics and diagnostics in the p53 pathway | |
AUPQ766900A0 (en) | Post bracket | |
AU2001261817A1 (en) | Method for displaying rich content | |
AU2001271641A1 (en) | Stable radioiodine conjugates and methods for their synthesis | |
AU2002363756A1 (en) | Determining progesterone cycles in livestock | |
EP1270756A4 (fr) | Alliage supermagnetostrictif et procede d'elaboration | |
AU2001293240A1 (en) | Methods for identifying novel therapeutic agents | |
TW563959U (en) | Device for improving power factor | |
GB0009756D0 (en) | Test method | |
AU2001241047A1 (en) | Pyridonecarboxylic acid derivatives | |
AU3713801A (en) | Animation technology | |
AU2001281417A1 (en) | Post | |
AUPR181900A0 (en) | Posts |